Furthermore, using a syngeneic graft model of STS, we showed that enhancing this pathway by combining the STING agonist ADU-S100 with doxorubicin could potentiate the antitumor activity via the upregulation of innate immune response signaling. This evidence concerns the gene STING1 and telomere syndrome.